Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 ELECTRa registry patient flow diagram presenting the proportion of patients of the total enrolled patient ... Figure 1 ELECTRa registry patient.

Published byArabella Long Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1 ELECTRa registry patient flow diagram presenting the proportion of patients of the total enrolled patient ... Figure 1 ELECTRa registry patient."— Presentation transcript:

1 Figure 1 ELECTRa registry patient flow diagram presenting the proportion of patients of the total enrolled patient ... Figure 1 ELECTRa registry patient flow diagram presenting the proportion of patients of the total enrolled patient cohort of the registry under chronic anticoagulation (AC) and antiplatelet (AP) therapy. Details are provided on the AC and AP agent chronically prescribed as well as the pre-operative strategies. ASA, acetyl salicylic acid; DOAC, direct oral anticoagulants; LMWH, low-molecular weight heparin; VKA, vitamin K antagonist. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Europace, euz062, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2 Comparison of major and minor complication rate between patients not treated with AT, treated with AP, with ... Figure 2 Comparison of major and minor complication rate between patients not treated with AT, treated with AP, with AC, and both AP + AC. AC, anticoagulants; AP, antiplatelets. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Europace, euz062, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3 Comparison of all-cause and procedure-related death rates between patients not treated with AT, treated with ... Figure 3 Comparison of all-cause and procedure-related death rates between patients not treated with AT, treated with AP, with AC, and both AP + AC. AC, anticoagulants; AP, antiplatelets. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Europace, euz062, The content of this slide may be subject to copyright: please see the slide notes for details.

4 Figure 4 Comparison of haematoma (requiring revision) and pulmonary embolism (PE) not requiring surgery rates between ... Figure 4 Comparison of haematoma (requiring revision) and pulmonary embolism (PE) not requiring surgery rates between patients not treated with AT, treated with AP, with AC, and both AP + AC. AC, anticoagulants; AP, antiplatelets. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Europace, euz062, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1 ELECTRa registry patient flow diagram presenting the proportion of patients of the total enrolled patient ... Figure 1 ELECTRa registry patient."

Similar presentations

Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.

Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.
Figure 1 Subject phenotypes and most common genotype in subjects enrolled in THAOS in continental Western Europe. Data ... Figure 1 Subject phenotypes.

Figure 1 Subject phenotypes and most common genotype in subjects enrolled in THAOS in continental Western Europe. Data ... Figure 1 Subject phenotypes.
Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.

Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Figure 1 Multivariable-adjusted predictors of PAC

Figure 1 Multivariable-adjusted predictors of PAC
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.

Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Fig. 1 Bone scintigraphy of the right tibia of the patient at disease onset (A), after 10 years of calcitonin ... Fig. 1 Bone scintigraphy of the right.

Fig. 1 Bone scintigraphy of the right tibia of the patient at disease onset (A), after 10 years of calcitonin ... Fig. 1 Bone scintigraphy of the right.
Figure 1. Multivariable-adjusted hazard ratios (solid line) for incident chronic obstructive pulmonary disease as a ... Figure 1. Multivariable-adjusted.

Figure 1. Multivariable-adjusted hazard ratios (solid line) for incident chronic obstructive pulmonary disease as a ... Figure 1. Multivariable-adjusted.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
AHA: American Heart Association; ALT: ...

AHA: American Heart Association; ALT: ...
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
Figure 1 Comparison of MITRA-FR and COAPT trial outcomes

Figure 1 Comparison of MITRA-FR and COAPT trial outcomes

Similar presentations

Ads by Google